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1. Introduction 
Chronic allograft nephropathy (CAN) remains the main cause of renal transplant loss 
besides the death of patients with a functioning graft. Its prevention and treatment still lacks 
any significant breakthrough since many years (Meier-Kriesche et al. 2004; Pascual et al. 
2002). Pathological manifestations of CAN include interstitial fibrosis, tubular atrophy, 
vascular occlusive changes, glomerulosclerosis and a progressive renal dysfunction 
accompanied by hypertension and proteinuria (Joosten et al.  2005; Racusen et al.  1999). This 
histopathologic constellation is now more formally and descriptively referred to as 
interstitial fibrosis and tubular atrophy (IF/TA) without evidence of any specific aetiology 
(Solez et al. 2007). IF/TA or CAN describe the common final path of different injuries 
causing renal damage, whereas their precise pathogenesis is complex and only incompletely 
understood (Joosten et al. 2005). The process encompasses multifactorial aetiologies 
including alloantigen-dependent as well as alloantigen-independent factors (Gottmann et al. 
2003; Joosten et al. 2005; Kerjaschki et al. 2006; Nankivell et al. 2003; Reuter et al. 2010; Tullius 
& Tilney, 1995). Hence, an effective treatment is not available so far. 
Rho effectors Rho-associated, coiled-coil containing protein kinases (ROCK) and their 
associated signaling pathways have emerged as important players in cardiovascular and 
renal pathophysiology. Recently, it has been shown that ROCK inhibition is protective in 
diabetic and obstructive nephropathy, hypertensive nephrosclerosis, ischemia reperfusion 
injury, and chronic allograft nephropathy (Kanda et al. 2003a; Kentrup D. et al. 10 A.D.; 
Kentrup D. et al. 2010; Komers et al. 2011a; Komers et al. 2011b; Liu et al. 2009; Nagatoya et al. 
2002; Nishikimi et al. 2004a; Satoh et al. 2002; Song et al. 2008; Versteilen et al. 2011).  
ROCKs have been initially identified as downstream targets of the small GTP binding 
protein Rho. Members of the Rho family include Rho (isoforms A–E, and G), Rac (isoforms 1 
and 2), Cdc42 and TC10 (Nobes & Hall, 1994). After translocation to the plasma membrane, 
GTP-RhoA activates its effectors, including the two isoforms of ROCK, ROCK1 (ROK┚, 
p160ROCK) and ROCK2 (ROK┙, Rho kinase) (Nakagawa et al. 1996). Although, ROCK1 and 
2 can be differentially regulated under distinct circumstances there is no evidence that 
ROCK1 and ROCK2 have different functions at present (Nobes & Hall, 1994). ROCKs are 
protein serine/threonine kinases belonging to the AGC (PKA/PKG/PKC) family (Ishizaki et 
al. 1996; Leung et al. 1995; Matsui et al. 1996). ROCK activity is involved in actin cytoskeletal 
organization, stress fiber formation, and cell contraction thereby controlling vascular 
smooth muscle contraction, endothelial barrier and leukocyte functions (e.g., cellular 
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motility, migration, adhesion and transmigration) (Loirand, Guerin & Pacaud, 2006; Riento 
& Ridley, 2003). Both isoforms of ROCK can be the target of effective inhibitors such as TAT-
C3, HMG-CoA reductase inhibitors, mTOR inhibitors, angiotensin II antagonists, Rad 
GTPase, dominant-negative ROCK, and the specific ROCK inhibitors fasudil, 
hydroxyfasudil, and Y-27632 (Liao, Seto & Noma, 2007; Oka et al. 2008). We herein discuss 
favourable effects of ROCK inhibitors in kidney transplantation-related diseases, and 
highlight their potential impact on novel therapeutic strategies to improve long-term renal 
graft survival. 
1.1 Rock Inhibition in Diabetic nephropathy 
Diabetic nephropathy (DN) is the most common cause of chronic kidney disease (CKD) with 
a considerable risk of progression to end stage renal disease (ESRD) (Zimmet, Alberti & 
Shaw, 2001). Thus, it is not surprising that DN is the main cause of patients entering 
permanent renal replacement programs (dialysis/transplantation) worldwide (Rugg, 2003). 
When dialysis is initiated, the survival of patients with DN is inferior when compared with 
other renal diseases. Despite an inferior survival of diabetics, which is primarily due to 
cardiovascular disease generally present prior to transplantation, kidney transplantation has 
been established as the renal replacement therapy of choice for these patients (Cosio et al. 
2008). Because longer waiting times on dialysis negatively impact post-transplant graft 
survival (Meier-Kriesche et al. 2000) and successful transplantation was shown to confess a 
substantial survival benefit to patients with diabetic-ESRD, transplantation should be 
performed early (Becker et al. 2006; Hirschl, 1996; Son et al. 2010; Wolfe et al. 1999). As 
diabetes persists (or occurs, e.g. post-transplant diabetes (Rodrigo et al. 2006)) after renal 
transplantation it contributes to delayed graft function and long-term (re-)graft loss (Arnol 
et al. 2008; Fellstrom et al. 2005; Khalkhali et al. 2010; Parekh, Bostrom & Feng, 2010; 
Wilkinson et al. 2005). Interestingly, in a study by Wiesbauer et al. maximal glucose, HbA1c, 
or diabetes treatment did not influence death-censored functional graft survival but 
mortality (Wiesbauer et al. 2010). However, there is evidence that DN can re-occur after 
transplantation and that reversal or stabilization of the course of DN (still difficult to 
achieve) may slower the progress to ESRD again (Bhalla et al. 2003; Osterby et al. 1991; Salifu 
et al. 2004; Wojciechowski, Onozato & Gonin, 2009). 
What happens in DN? The mechanistic driving force of DN still remains undetermined. Only 
30-50% of people with diabetes develop overt nephropathy over a lifetime. This suggests that 
other factors besides diabetes are required to share in for the progression of DN (Nakagawa et 
al. 2011; Rugg, 2003). One important parameter for the development of DN identified is 
glomerular hypertension due to (intra renal) vascular alterations (Johnston et al. 1998). 
Vascular damage of the glomerular capillaries causes leakage of albumin and other proteins 
across the filter into the urine. It was postulated that the degree of DN correlates to the amount 
of urinary albumin excretion. However, others have found that DN is an independent risk 
factor for the development of microalbuminuria (Chang et al. 2011a). In contrast, progressive 
renal failure in diabetics can also occur in the absence of proteinuria even though histology 
present with typical signs of DN (Caramori, Fioretto & Mauer, 2003). Thus, it was questioned 
whether the decline of renal function is linked to proteinuria or whether both simply appear in 
parallel (Perkins et al. 2007) (reviewed in (Jefferson, Shankland & Pichler, 2008)). Because 
classical cardiovascular risk factors like hyperglycemia, hypertension, and hyperlipidemia are 
well-described to promote DN it would stand to reason that mechanisms causing vascular 
damage, such as endothelial dysfunction, oxidative stress, advanced glycation end products 
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(AGEs), and angiogenesis, are involved in the pathogenesis of DN (Brownlee, 2001; Chang et 
al. 2011b; Jansson, 2007). It was suggested that hyperglycemia accelerates the polyol and the 
hexosamine pathway, activates protein kinase C (PKC), and induces nonenzymatic 
glycosylation AGEs (Brownlee, 2001; Schena & Gesualdo, 2005). Especially AGEs lead to 
fibrosis via accumulation of interstitial collagens. AGEs also induce oxidative stress which 
activates NF-kappa b. NF-kappa b and PKC-activation are associated with the release of 
(proinflammatory) cytokines and growth factors such as vascular endothelial growth factor 
(VEGF), tumor necrosis factor a (TNFa), fibroblast growth factor (FGF), tissue factor, 
transforming growth factor-beta (TGF-ß), Interleukin 1 (IL-1), IL-6 and IL-18 (Brownlee, 2001; 
Johnston et al. 1998). PKC activation is also related to hemodynamic changes (predominantly 
through the activation of the renin-angiotensin aldosterone system (RAAS) which in term 
promotes hypertension, oxidative stress, and fibrosis.  
Therefore, current renoprotective treatment strategies for DN are rather classical and include 
the control of blood glucose, blood pressure, lipids (notably, many cholesterol-independent or 
"pleiotropic" effects of statins are mediated by ROCK inhibition (Liao, 2007)) and body weight 
as well as RAAS blockade and physical training (Alicic & Tuttle, 2010; Van Buren & Toto, 
2011). The interest emerged on ROCK inhibitors when it was observed that Rho/ROCK play 
important roles in hypertension/cardiovascular system and in the kidney in models of 
diabetes (Arita et al. 2009; Gojo et al. 2007; Kawamura et al. 2004; Kolavennu et al. 2008; Miao et 
al. 2002; Peng et al. 2008; Rikitake & Liao, 2005). Besides hyperglycemia, further factors of the 
diabetic milieu, such as reactive oxygen species (ROS), oxidized LDL, acceleration of the 
hexosamine pathway, and AGEs, can activate the Rho/ROCK pathway in vascular and renal 
cells (Komers, 2011). Interestingly, among other actions AGEs can increase endothelial 
permeability/hyperpermeability of vessels through the RAGE/Rho signaling pathway which 
can be inhibited by application of Y-27632 (Hirose et al. 2010). Moreover, Rho/ROCK have 
been identified as key mediators of VEGF-induced endothelial cell hyperpermeability (Zeng et 
al. 2005). As mentioned above, VEGF expression is increased in response to hyperglycemia. 
Because albuminuria, due to glomerular leakage, is a common feature of DN, ROCK activity 
might be a mechanism involved in renal proteinuria in these patients. In addition, the 
Rho/ROCK pathway can be activated by hormones or cytokines involved in DN 
pathophysiology, like AngII, aldosterone, TGF-ß, and VEGF (Komers, 2011). It was stated that 
this activation of ROCK-dependent pathways, e.g. due to production of osteopontin, 
plasminogen activator inhibitor 1, or extracellular matrix, is involved in the pathogenesis of 
DN. Cell culture studies by Peng et al. and Kolavennu et al. supported these findings. They 
observed that the activity of Rho/ROCK in mesangial cells increased by glucose treatment. 
This caused reorganization of cytoskeleton and increased production of fibronectin, collagen 
IV, VEGF and AP-1, a transcription factor promoting the expression of e.g. TGF-ß. Inhibition of 
the Rho/ROCK pathway saved the cells from these changes (Kolavennu et al. 2008; Peng et al. 
2008). Moreover, glomerular hypertension is a well described factor participating in the 
progression of DN. Hypertension causes mechanical stress which activates Rho (see below). In 
congruence, Komers et al. described improved renal hemodynamics after ROCK inhibition in 
diabetic rats (Komers et al. 2011a). In addition, there is some evidence that Rho is involved in 
the actions of endothelin 1 (ET-1), a potent vasoconstrictor, which is upregulated in diabetics 
(Yousif, 2006). 
Because of this and comparable evidence from other studies it was assumed that ROCK 
inhibition is advantageous in diabetes. Komers, Peng and Gojo et al. treated diabetic rats 
(diabetes type 1 model) with the orally administered ROCK-inhibitor fasudil (Gojo et al. 
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2007; Komers et al. 2011b; Peng et al. 2008). Their diabetic rats rapidly developed 
albuminuria, glomerulosclerosis, and renal interstitial fibrosis, as well as decreased 
glomerular filtration rates (GFR), and increased expression of molecular markers of DN. 
Sustained ROCK inhibition reduced diabetes-related kidney damage (as confirmed by 
histology and urinalysis) in the kidney and expression of the molecular markers (including 
markers of epithelial–mesenchymal transition (EMT)) in association with a slight anti-
proteinuric effect (including beneficial effects of fasudil on podocyte foot process 
effacement) which was independent of blood pressure or glucose control. So far, all long-
term studies evidenced nephroprotective effects of ROCK inhibitors being independent 
from systemic blood pressure. In contrast, Kikuchi et al. failed to suppress the progression 
of nephropathy by fasudil application (but ameliorated some features of DN) in a rat model 
of type 2 diabetes (Kikuchi et al. 2007) but Kolavennu et al. found ROCK inhibition being 
kidney protective in type 2 diabetes mice (Kolavennu et al. 2008). Interestingly, Peng 
observed that fasudil and ACE-inhibitors had a comparable effectiveness preventing DN 
while Komers et al. noted that the combination of fasudil and losartan was not more 
effective than losartan alone (Komers et al. 2011b; Peng et al. 2008). ACE-inhibitors and AT1-
blockers are well known agents used for kidney protection in (proteinuric) DN for many 
years. Interestingly, RAAS blockade was effective to inhibit Rho/ROCK activity in several 
studies suggesting that ROCK activation might follow AT1 activation under certain 
conditions (Higuchi et al. 2007; Komers et al. 2011b; Ohtsu et al. 2006). Thus, the effects of 
RAAS blockade partly rely on ROCK inhibition: Angiotensin II (AngII) mediated 
vasoconstriction (via myosin light chain phosphorylation), proinflammatory effects (via 
PAI-1 and monocyte chemoattractant protein-1 (MCP-1) induction) and JNK-dependent 
hypertrophy/cell migration. They can be attributed to Rho activity and are therefore within 
the therapeutic target range of ROCK inhibitors (Higuchi et al. 2007; Ohtsu et al. 2006). More 
evidence comes from Rikitake et al. who showed in ROCK1+/- haploinsufficient mice that 
perivascular fibrosis induced by AngII was significantly lower than in wild type individuals 
(Rikitake et al. 2005b). In the context of diabetes it is of note that AngII-dependent activation 
of the Rho/ROCK pathway is partly mediated by NADPH oxidase-dependent ROS (Jin et al. 
2006). As mentioned above, ROS are present in the hyperglycemic milieu in excess probably 
promoting AngII effects in diabetics.  
1.2 Rock Inhibition in Urethral obstruction 
Urethral obstruction (UO) is a typical cause of ESRD in children. In this patient group, UO is 
responsible for approximately 15 to 25% of kidney failures (Koo et al. 1999). This is even a 
problem after renal transplantation, because obstruction-related side effects influence the 
success of transplantation. Allograft function and survival are often limited due to urinary 
tract infection or surgical complications, implying deleterious actions of chronic elevated 
intravesical pressure (Cairns et al. 1991; Churchill et al. 1988; Sheldon et al. 1994). However, 
more recent studies claim that patients with severe lower urinary tract abnormalities and 
ESRD may receive a kidney transplant with comparable safeness and success to patients 
without abnormalities (Broniszczak et al. 2010; Nahas & David-Neto, 2009; Rigamonti et al. 
2005).  
In experimental settings, UO is commonly employed as a normotensive, non-proteinuric 
and non-hyperlipidemic model of tubulointerstitial fibrosis without any toxic renal insult 
(Nagatoya et al. 2002). Fibrosis is of major interest, not only because it is a common final 
path of different injuries causing renal damage, but, as a substantial part of IF/TA, also 
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related to the renal (graft) prognosis (Couser & Johnson, 1994; Meier-Kriesche et al. 2004; 
Morgan et al. 2011; Nath, 1992; Pascual et al. 2002). Depending on the side where it mainly 
occurs, fibrosis is classified as glomerulosclerosis or tubulointerstitial fibrosis. Nevertheless, 
in most situations fibrosis is detected in both compartments, hinting towards a not yet fully 
understood cross-talk in between (Klein et al. 2011). Briefly, examples of fibrosis initiating 
factors are: increased intravascular pressure (hypertension), increased pressure in the 
tubular lumen (due to obstruction of the urinary tract), hyperglycemia (diabetes), increased 
urinary albumin concentrations (proteinuria), and toxic substances (puromycin or 
adriamycin). After ignition of the process due to different stimuli the pathways converge 
independently of the activator. Signaling includes induction of cytokines and chemokines, 
like TGF-┚, platelet-derived growth factor (PDGF), FGF, ET-1, and osteopontin, leading to 
renal inflammation (predominant cell types are monocytes and macrophage (Mphi)) and 
cell activation.  
It was suggested that Mphi are central players in the fibroproliferative response (Vernon, 
Mylonas & Hughes, 2010). They release profibrogenic growth factors i.e., TGF-┚, PDGF and 
FGF, which activate/recruit myofibroblasts and stimulate resident interstitial fibroblasts. 
These fibroblasts are the main source of interstitial ECM (e.g., collagens and fibronectin, and 
expression of factors interfering with ECM crosslinking (transglutaminases, high glucose-
induced AGEs) and/or turnover (matrix metalloproteinases, plasminogen activator, and 
their inhibitors) (well summarized in (Klein et al. 2011)) that cause fibrosis. In congruence, 
we and others observed e.g., that the level of L-Plastin, a cytoskeletal protein mainly 
expressed in interstitial fibroblasts, is increased in IF/TA (Reuter et al. 2010). Recently, it was 
reported that Rho/ROCK are central to differentiation, migration, and contractility of 
myofibroblasts (Mack et al. 2001; Parizi, Howard & Tomasek, 2000). Thus, ROCK inhibition 
might suppress the destructive activity of myofibroblasts. If not applied, the fibrotic process 
continues. Blocking of Mphi recruitment and activation ameliorates renal inflammation and 
fibrosis (Vielhauer et al. 2010). As ROCK is essential for Mphi migration its blockade can 
protect from fibrosis in UO (Nagatoya et al. 2002; Satoh et al. 2002). In renal graft recipients 
TGF-ß expression was analyzed in protocol biopsies (performed 3, 6, and 12 months after 
kidney transplantation). An increased level of TGF-ß was associated with a larger extent of 
interstitial fibrosis (Baboolal et al. 2002). Interestingly, when ROCK is inhibited in vivo the 
tissue level of the fibrogenic TGF-ß is lower than in control kidneys (Nagatoya et al. 2002).  
Besides, TGF-ß promotes EMT, a process related to the development of renal fibrosis (Zavadil 
& Bottinger, 2005). As mentioned before, Rho/ROCK are important players in the (re-
)organisation of the cytoskeleton. This implies that they are key mediators/effectors of 
epithelial plasticity and EMT induced by TGF-ß (Patel et al. 2005; Rodrigues-Diez et al. 2008; 
Zavadil & Bottinger, 2005). In summary, kidney protection due to ROCK inhibition can be 
achieved in UO because Rho/ROCK is involved in different key mechanisms in renal fibrosis. 
1.3 Rock Inhibition in Hypertensive Nephrosclerosis 
Increased blood pressure is an important health problem and a major risk factor for 
cardiovascular morbidity and mortality throughout the world (Staessen et al. 2003). To date, 
both the pathogenesis of arterial hypertension and the molecular mechanisms involved in 
blood pressure control remain poorly understood. Hypertension is characterized by high 
arterial pressure resulting from increased peripheral vascular resistance that can be 
attributed to both enhanced contractility of vascular smooth muscle cells and arterial wall 
remodeling. Increased activity of the Rho/ROCK pathway has been proposed to play an 
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important role in the development and maintenance of hypertension. In various animal 
models of experimental hypertension a role of RhoA and ROCK has been demonstrated. 
Blocking ROCK activity with Y-27632 has blood pressure lowering effects in spontaneously 
hypertensive rats (SHR), deoxycorticosterone-acetate (DOCA)/salt-treated and renal 
hypertensive rats (Uehata et al. 1997). Similarly, oral administration of fasudil to SHR rats 
significantly lowered blood pressure (Mukai et al. 2001). In addition, several studies have 
addressed changes in RhoA activity in isolated vascular segments from hypertensive 
animals suggesting that increased RhoA activity is responsible for enhanced ROCK function 
in the pathology of hypertension. In mesenteric and cerebral arteries from SHR and 
normotensive rats the relaxation induced by treatment with Y-27632 was markedly higher in 
arteries from SHR rats (Asano & Nomura, 2003; Chrissobolis & Sobey, 2001). This has also 
been shown for mesenteric arteries from DOCA/salt-treated rats (Weber & Webb, 2001). In 
animals treated with L-NAME, an inhibitor of NO-synthase, oral administration of Y-27632 
lowered blood pressure and the level of active, GTP-bound RhoA was markedly increased 
in vessels from L-NAME treated rats (Weber & Webb, 2001). Similarly, direct evidence for 
increased amounts of active RhoA have been found in stroke-prone SHR, DOCA/salt- and 
renal hypertensive rats (Moriki et al. 2004; Seasholtz et al. 2001; Seko et al. 2003). Analysis of 
the expression levels of RhoA has led to controversial results with some studies showing an 
increased expression of RhoA under hypertensive conditions (Seasholtz et al. 2001) whereas 
in other reports no differences in the expression profile of proteins from the RhoA/ROCK 
pathway have been detected (Seko et al. 2003). 
Impaired endothelial function and decreased NO-production have been implicated in the 
etiology of hypertension. Decreased expression of endothelial nitric oxide synthase (eNOS) 
is found in aortae from SHR rats (Chou et al. 1998) and eNOS-deficient mice have an 
elevated blood pressure (Huang et al. 1995). Interestingly, there seems to be extensive 
crosstalk between NO and RhoA/ROCK-signaling. There is compelling evidence that the 
NO/cGK pathway leads to an inhibition of RhoA/ROCK signaling (Carter, Begaye & 
Kanagy, 2002; Chitaley & Webb, 2002; Sauzeau et al. 2000). On the other hand, the 
RhoA/ROCK cascade seems to reciprocally influence NO-signaling. The mechanism by 
which ROCK influences NO production seems to be the regulation of eNOS mRNA stability 
(Eto et al. 2001; Rikitake et al. 2005a; Takemoto et al. 2002). 
Chronic hypertension leads to end organ damage in a substantial number of patients. 
Hypertensive nephrosclerosis is a disorder that is usually associated with chronic 
hypertension. Histologically it is characterized by vascular, glomerular, and 
tubulointerstitial changes. The vascular pathology consists of intimal thickening and 
luminal narrowing of the large and small renal arteries and the glomerular arterioles. Two 
different processes appear to contribute to the development of the vascular lesions: A 
hypertrophic response to chronic hypertension evident by medial hypertrophy and 
fibroblastic intimal thickening, resulting in narrowing of the vascular lumen (Zucchelli & 
Zuccala, 1994). In the beginning this process is adaptive by minimizing the degree to which 
the rise in systemic pressure is transmitted to the downstream arterioles and capillaries 
(Zucchelli & Zuccala, 1994). The other process contributing to the vascular pathology is the 
deposition of hyaline-like material (plasma protein constituents, such as inactive C3b, part 
of the third component of complement) into the damaged, more permeable arteriolar wall 
(Zucchelli & Zuccala, 1994). Arterial hypertension may lead to focal global (involving the 
whole glomerulus) or focal segemental glomerulosclerosis (Marcantoni et al. 2002; Zucchelli 
& Zuccala, 1994). Global sclerosis is thought to reflect ischemic injury, leading to nephron 
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loss (Marcantoni et al. 2002). Focal segmental sclerosis is typically associated with 
glomerular enlargement, which is probably a compensatory response to nephron loss 
(Harvey et al. 1992). The vascular and glomerular alterations are associated with an often 
severe interstitial nephritis. Its etiology is incompletely understood. At least in part 
immunologic processes may be involved. They are probably started by ischemia-induced 
alterations in antigen expression on the surface of the tubular epithelial cells (Truong et al. 
1992). Nephrosclerosis is seen with aging but is clearly exacerbated in arterial hypertension 
(Lindeman, Tobin & Shock, 1984; Rule et al. 2010). The incidence of progressive renal disease 
in hypertensive nephrosclerosis is low, however, three groups of patients are at increased 
risk to develop progressive kidney function deterioration: patients with more marked 
elevations in blood pressure, afro-american patients (they have an approximate eight-fold 
elevation in the risk of hypertension-induced ESRD(Toto, 2003); this increase in risk may 
persist even with "adequate" blood pressure control) and patients with underlying chronic 
kidney disease, especially diabetics. Patients with nephrosclerosis typically present with a 
long history of hypertension. If present, decline in kidney function is slow in progression as 
indicated by serum-creatinine and blood-urea-nitrogen. Urinalysis is typically benign 
without appearance of cast or dsymorph erythrocytes. Urinary protein excretion is typically 
mildly elevated (less than 1 gram per day). Concerning the incidence of renal failure in 
hypertensive nephrosclerosis there seems to be a clinical paradox as among patients 
(especially considering afro-americans) entering the chronic hemodialysis program. 
Hypertensive nephrosclerosis is one of the most common diagnoses, whereas the risk for a 
hypertensive patient to develop ESRD is rather small. However, at least three large trials 
might explain this paradox: the number of hypertensive patients is so large that even a small 
percentage of patients at risk gives a large number; the rate of progression might be so slow 
that trials that mostly run over 5-7 years might not detect patients at risk (Freedman, 
Iskandar & Appel, 1995; Madhavan et al. 1995). Recent work has shed some light on the 
importance of the Rho/ROCK pathway in kidney disease. ROCK is constitutionally active in 
the renal circulation. Studies on glomerular hemodynamics demonstrated that ROCK 
inhibition by Y-27632 and fasudil dilates the basal tone of afferent and efferent arterioles 
(Cavarape et al. 2003; Nakamura et al. 2003). Importantly, both inihibitors reverse 
angiotensin II-induced vasoconstriction of efferent and afferent arterioles (Nakamura et al. 
2003). Thus, ROCK inhibition might protect against deleterious hemodynamic effects in 
kidney disease. In addition, to its critical role for the renal microvasculature the Rho/ROCK 
pathway is an important regulator of several cell function including proliferation, migration 
and apoptosis as already stated above (diabetic nephropathy). Of importance for the 
development of glomerulosclerosis, as a key feature of hypertensive nephrosclerosis, it has 
been demonstrated that Rho regulates the formation of stress fibers, focal adhesions and 
peripheral bundles through reorganization of the actin cytoskeleton in a renal epithelial cell 
line (Nakano et al. 1999). Renal epithelial cells are able to transform to mesenchymal-like 
cells via EMT. These changes have been observed in renal tubulointerstitial fibrosis, another 
hallmark of hypertensive nephrosclerosis. Mesangial cells reside in the renal glomeruli and 
produce ECM. Its increased accumulation causes glomerulosclerosis, where TGF-ß has been 
shown as a causative factor (Nakano et al. 1999). As mentioned above Rho/ROCK are key 
mediators/effectors of epithelial plasticity and EMT induced by TGF-ß (Patel et al. 2005; 
Rodrigues-Diez et al. 2008; Zavadil & Bottinger, 2005). Finally, in mesangial cells, mechanical 
stress, which is considered to cause glomerular hypertension and glomerulosclerosis, 
enhances mitogen-activated protein kinase (MAP kinase) activity, stress fiber formation, and 
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cellular proliferation (Bruijn et al. 1994). In this process of disease the Rho/ROCK pathway 
plays a pivotal role, acting as a modulator of MAP kinase and the downstream cellular 
impact. Taken together, these data strengthen an important role of the Rho/ROCK pathway 
in the development of glomerulosclerotic disease. 
Podocytes are highly differentiated cells that are located in the renal glomerulus. 
Cytoskeleton rearrangement is closely associated with podocyte shape changes and 
dysfunction in various renal diseases (Zucchelli & Zuccala, 1994). Using the ROCK-
inhibitor Y-27632 Endlich et al. could inhibit the reorganization of the cytoskeleton 
induced by mechanical stress in podocytes. Moreover, inhibition of ROCK prevents TGF-
ß-induced increase in CTGF accumulation in fibroblast cells (Heusinger-Ribeiro et al. 
2001). All these observation strongly suggest a pivotal role of the Rho/ROCK pathway in 
the progression of renal injury. To date, the body of evidence given by in vivo studies is 
growing. As the Rho/ROCK pathway regulates glomerular hemodynamics and has 
profound effects on mesangial cell proliferation and matrix production, ROCK-inhibitors 
are candidates to serve as therapeutic tools to treat glomerulosclerotic disease. Thus, it has 
been demonstrated that Y-27632 and fasudil prevent tubulointerstitial fibrosis in a model 
of unilateral ureteral obstruction [for detail see section on ureteral obstruction]. In 5/6 
nephrectomized spontaneously hypertensive rats (SHR), a model of hypertensive 
glomerulosclerosis, the Rho/ROCK pathway was activated. Treatment with fasudil 
reduced urinary protein excretion, improved glomerular and tubulointerstitial injury 
score, and reduced the infiltration of ED-1 positive cells and proliferating cell nuclear 
antigen positive cells in the kidney of SHR treated by 5/6 nephrectomy. Interestingly, 
these effects were obtained without lowering blood pressure, indicating blood pressure-
independent effects of ROCK (Kanda et al. 2003b). Fasudil up-regulated the expression of 
p27kip1, a cyclin-dependent kinase inhibitor, and increased the p27kip1 immunopositive 
cells in both glomeruli and tubulointerstitium, indicating inhibition of cell proliferation 
and macrophage recruitment under fasudil treatment. Another group reported similar 
beneficial effects in Dahl salt-sensitive rats. In these animals, fasudil improved renal 
function, proteinuria, and histological findings without changes in blood pressure 
(Nishikimi et al. 2004b). These beneficial effects were most likely accompanied by 
decreased expression of TGF-ß, collagen-I, and collagen-III mRNA in the renal cortex. In 
salt-loaded spontaneously hypertensive stroke-prone rats serving as a model of severe 
hypertension fasudil improved kidney function, proteinuria, histological findings and 
decreased expression of genes encoding for extracellular matrix, oxidative stress, 
adhesion molecules and antifibrinolysis. Of note, these effects were independent of the 
blood pressure-lowering activity of fasudil (Nishikimi et al. 2004b). As stated above there 
is compelling evidence for an extensive crosstalk between NO and RhoA/ROCK-
signaling. Indeed, in SHR fasudil partly reversed the progressive nephrosclerosis initiated 
by administration of the nitric oxide-synthase inhibitor nitro-L-arginine methyl ester 
(Koshikawa et al. 2008). 
Although multiple factors contribute to the development and progression of chronic renal 
disease, the renin-angiotensin-aldosterone system seems to be of major importance. 
Angiotensin II is considered to be the main mediator of this system. It is a potent 
vasoconstrictor acting directly on vascular smooth muscle cells, thereby regulating the 
vascular tone. Besides it alters renal sodium and water absorption by stimulating synthesis 
and secretion of aldosterone. Further, it is involved in the generation of thirst and the 
excretion of vasopressin. Hence, it has a pivotal role in acute and chronic regulation of blood 
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pressure. Studies in chronic renal disease have shown that angII contributes to deterioration 
of renal function even if blood pressure is unaltered (Anderson, Rennke & Brenner, 1986). In 
this view it is important to keep in mind that angII activates ROCK in vascular smooth 
muscle cells (Yamakawa et al. 2000). In rats infused with angII, treatment with Y-27632 
reduced renal inflammatory cell infiltration and tubular damage. AngII activated nuclear 
factor-kappaB and initiated overexpression of proinflammatory factors, including TNF-
alpha and monocyte chemotactic protein-1 (MCP-1), and of CTGF. Treatment of angII-
infused rats with Y-27632 reduced the upregulation of these proinflammatory and 
profibrotic mediators (Ruperez et al. 2005). 
Taken together these studies imply that blockade of the Rho/ROCK pathway might prove 
beneficial in hypertensive nephrosclerosis. 
1.4 Rock Inhibition in Ischemia Reperfusion Injury 
Renal ischemia-reperfusion (IR) injury (IRI) is a common and important trigger of acute 
renal injury (AKI). It occurs in a broad spectrum of clinical settings including 
(transplantation) surgery, trauma, dehydration or sepsis leading to renal hypoperfusion, 
acute tubular necrosis (ATN), and functional disturbances - namely AKI. Inevitably linked 
to renal transplantation it is a well known risk factor for delayed graft function associated 
with prolonged hospitalization, elevated costs, and increased complexity of 
immunosuppressive drug management. Moreover, by reducing the overall number of 
nephrons and increasing the risk of acute rejection episodes, IRI might cause a significantly 
reduced graft survival. Involving both, the innate and the adaptive immune response, 
causing subsequent sterile inflammation, IRI is composed of a complex cascade of events 
including the generation of reactive oxygen and nitrogen species, chemotaxis, and 
phagocytosis. All of which are functional properties of the key effectors of the inflammatory 
cascade, neutrophiles, the most abundant leukocyte population in circulation, which 
accumulate as early as 30 minutes after IR particularly in the peritubular capillary network 
of the outer medulla (Li et al. 2008). Attracted leukocytes subsequently transmigrate into the 
interstitium. This is associated with increased vascular permeability and loss of endothelial 
and tubular epithelial cell integrity (Awad et al. 2009) due to degranulation of neutrophils. 
Upon activation these neutrophils release proteases, myeloperoxidase, cytokines, and 
generate reactive species leading to aggravation of injury and damage of endothelial and 
epithelial cells especially in the outer medulla (Bolisetty & Agarwal, 2009; Jang & Rabb, 
2009; Li & Okusa, 2006; Okusa et al. 2000). In regard to this, it has recently been shown that 
ROCK) and their associated signaling pathways play pivotal roles in the development of 
(experimental) IRI. ROCK-inhibitors such as fasudil or Y-27632 have been shown to provide 
beneficial effects concerning different ischemic events such as renal (Kentrup D. et al. 10 
A.D.; Kentrup D. et al. 2010; Prakash et al. 2008; Teraishi et al. 2004; Versteilen et al. 2006; 
Versteilen et al. 2011) myocardial (Bao et al. 2004; Hamid, Bower & Baxter, 2007; Wolfrum et 
al. 2004), cerebral (Satoh et al. 2008; Toshima et al. 2000), hepatic (Du & Hannon, 2004; Ikeda 
et al. 2003; Takeda et al. 2003), and gastrointestinal (Santen et al. 2010) ischemia. However, 
the exact mechanisms involved remain to be fully elucidated.  
In the context of IRI it seems to be of interest that ROCKs are involved in the regulation of 
leukocyte cellular motility, migration, adhesion, and transmigration (Alblas et al. 2001; 
Honing et al. 2004; Lee et al. 2004; Samaniego et al. 2007; Takesono et al. 2010; Vemula et al. 
2010; Worthylake et al. 2001; Worthylake & Burridge, 2003) Regarding this, Teraishi et al. 
were the first group to test the effectiveness of ROCK-inhibitors in an animal model of renal 
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IRI. For this, male Sprague-Dawley rats underwent unilateral nephrectomy of the right 
kidney two weeks before inducing 45 min of warm ischemia in the remaining kidney by 
clamping the left renal artery and vein. Y-27632 was hereby applied 5 min pre ischemia or 5 
min post ischemia. They observed a protective effect for both treatments (i.e. improved renal 
function, less histological damage) which was based according to them on reduced 
infiltration by neutrophils as shown by myeloperoxidase assays. However, even though the 
latter is a non specific detection method and the data regarding the cell types typically 
involved varies, (e.g. due to the models used (Rabb et al. 2003; Thornton et al. 1989) or due to 
non specific detection methods, e.g. myeloperoxidase, naphthol chloroacetate esterase, or 
HIS-48 staining (Ysebaert et al. 2000)), it is well known that the increased influx of 
neutrophiles, T- and B-lymphocytes as well as macrophages/monocytes significantly 
contributes to the pathogenesis of AKI (Kinsey, Li & Okusa, 2008). This first study is also in 
congruence with later work by Versteilen et al.. By pre-treating male Wistar rats with Y-
27632 they could show that leukocyte accumulation (60-70% neutrophils) was markedly 
reduced by ROCK-inhibitor treatment in the microvasculature of the corticomedullary 
junction and medulla (Versteilen et al. 2011). They hypothesize that this may be partly due to 
NO-mediated effects via activated endothelial cells (i.e. limited expression of adhesion 
molecules and cytokines leading to attenuation of leukocyte accumulation), eNOS mediated 
alterations of the renal blood flow (Versteilen et al. 2006) and direct effects on the leukocytes. 
Further, Prakash et al. also applied the ROCK-inhibitor Y-27632 in a rat model of renal 
ischemia, but used a Y-27632-lysozyme conjugate (Prakash et al. 2008). Thus, they tried to 
guarantee a renal-specific uptake into proximal tubular cells via megalin receptors. In 
unison with the aforementioned data they describe substantially attenuated tubular damage 
as indicated by reduced expression of dedifferentiation markers kidney injury molecule 1 
(KIM-1) and vimentin. Additionally, they observed reduced fibrosis and inflammation as 
determined by reduced gene expressions of MCP-1, procollagen I┙1, TGF-┚1, tissue 
inhibitor of metalloproteinase 1 and ┙-smooth muscle actin, as well as reduced 
immunohistochemical staining of macrophage infiltration, ┙-smooth muscle actin, collagen 
I, collagen III and fibronection compared to untreated animals. However, in contrast to the 
previous data, they describe adverse systemic effects (e.g. leucopenia) when animals were 
treated with the unconjugated Y-27632, as performed by others groups. An effect, which 
cannot easily be explained due to the fact that the beneficial effects of ROCK-inhibitors have 
not only been shown for the kidney but for other organs as well. 
Although and apart from the above described effects, it has recently been shown by 
Kroening et al. that, in some cases, ROCK inhibition may not adversely influence the 
migratory capabilities of specific cell types as it has been repeatedly shown. Instead, at least 
in the case of tubular epithelial cells the migratory capacity may actually be promoted and 
thus ROCK inhibition may favor repair processes in renal tubules (Kroening et al. 2010). The 
beneficial effects of ROCK inhibition are further supported by work published by 
Unbekandt et al. who could show that transient ROCK inhibition allows cells from 
disaggregated embryonic kidneys to form ureteric bud and nephron epithelia (Unbekandt & 
Davies, 2010). Moreover, one last positive effect of ROCK inhibition related to the 
prevention of IRI mentioned might be that ROCK inhibition promotes cell survival in 
human stem cells (Watanabe et al. 2007) and is able to reduce apoptosis in conventional 
embryonic kidney culture (Meyer et al. 2006). 
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1.5 Rock Inhibition in Chronic Allograft Nephropathy 
Compared to hemodialysis kidney transplantation significantly reduces mortality when it is 
applied to the appropriate patient (Wolfe et al. 1999). However, even after renal 
transplantation mortality of transplant recipients is still increased when compared to the 
general population. This is mainly due to death from cardiovascular disease with a 
functioning graft as well as immunological and non-immunological factors resulting in graft 
loss. Despite introduction of new immunosuppressive drugs within the last two decades a 
substantial increase in graft survival was not achieved. Consequently prevention of graft 
loss and treatment still lack any significant breakthrough since many years (Gjertson, 1991; 
Lamb, Lodhi & Meier-Kriesche, 2011; Meier-Kriesche et al. 2004; Meier-Kriesche, Schold & 
Kaplan, 2004). The pathological manifestations seen in chronic graft loss were summarized 
as chronic allograft nephropathy. In the recent Banff-classification (“Banff `05”) which gives 
a classification of the different pathological features seen in chronic graft loss, the term 
chronic allograft nephropathy does no longer occur (Solez et al. 2007). The rationale for this 
update of the Banff schema was the misusage of CAN as a generic term for all causes of 
chronic renal allograft dysfunction with fibrosis that inhibits the accurate diagnosis and 
appropriate therapy. Thus, the authors of the Banff-classification aimed to present a 
pathological classification that specifies the underlying disease to facilitate causal treatment. 
Pathological manifestations of chronic allograft injury include interstitial fibrosis, tubular 
atrophy, vascular occlusive changes, glomerulosclerosis and a progressive renal dysfunction 
accompanied by hypertension and proteinuria (Cornell & Colvin, 2005). This 
histopathologic constellation is now more formally and descriptively referred to as 
interstitial fibrosis and tubular atrophy (IF/TA) without evidence of any specific aetiology 
(Solez et al. 2007). IF/TA or CAN describe the common final path of different injuries 
causing renal damage, whereas their precise pathogenesis is complex and only incompletely 
understood. The process encompasses multifactorial aetiologies including alloantigen-
dependent as well as alloantigen-independent factors (Cornell & Colvin, 2005). The latter 
mainly comprise arterial hypertension, chronic obstruction and calcineurin-inhibitor toxicity 
(Busauschina, Schnuelle & van der Woude, 2004; Klahr & Morrissey, 2003; Mihatsch, Ryffel 
& Gudat, 1995; Morozumi et al. 2004). Besides, chronic polyoma virus nephrotixicity can 
lead to IF/TA (Drachenberg et al. 2005). Recurrent and de novo glomerular or vascular 
diseases can also lead to glomerulosclerosis and IF/TA, both early and late post-transplant. 
It is important to mention that de novo diabetic changes are becoming more common in 
allografts. As mentioned chronic alloimmune injury is an important cause of IF/TA in 
kidney grafts. Data on alloantibodies and C4d, a product of the complement cascade in 
chronically failing grafts, hint at a pathogenic role for humoral immunity in chronic allograft 
injury. In a prospective study de novo appearance of donor-specific HLA-antibodies was 
associated with increased graft failure at one year (Terasaki & Ozawa, 2004). These data are 
consistent with the importance of immunological factors in chronic graft injury. 
The Rho/ROCK pathway is potentially crucial in mediating immunological as well as non-
immunological injury in chronic graft loss as it is involved in adhesion, migration, 
proliferation, and cytokine release (Amano et al. 1997; Chihara et al. 1997; Tharaux et al. 
2003). The activation of T-cells is involved in alloimmune responses. Here the Rho/ROCK 
pathway plays a pivotal role in T-cell activation during cellular immune responses by 
promoting structural rearrangements that are critical for T-cell signaling (Tharaux et al. 
2003). Besides, a role for Rho/ROCK in HLA class I signaling pathways that have been 
implicated in the process of chronic rejection has been shown. Ligation of HLA class I 
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molecules by anti-HLA-antibodies resulted in activation of Rho/ROCK and increased stress 
fiber formation. Inhibitors of Rho-GTPase and ROCK blocked HLA class I-mediated 
posphorylation of paxillin and FAK, both central elements of the focal adhesion signaling 
complex (Lepin et al. 2004). As stated above not only immunological factors but also non-
immunological factors, such as arterial hypertension, are responsible for chronic graft injury. 
Recent data also show relevance of the Rho/ROCK pathway for the regulation of 
hemodynamics and arterial hypertension. In 1997 it was shown that the Rho/ROCK pathway 
is involved in the generation of arterial hypertension in different animal models of 
hypertension (Uehata et al. 1997). Interestingly, these data were confirmed in hypertensive 
patients showing involvement of Rho/ROCK in the generation of the increased vascular tone 
in these patients (Masumoto et al. 2001). As already stated above there is a close interaction 
between the RAAS and the Rho/ROCK pathway. Activation of the RAAS in arterial 
hypertension and vascular disease is associated with increased activation of Rho/ROCK 
(Higashi et al. 2003; Yamakawa et al. 2000). Taken together accumulating data suggest a role of 
the Rho/ROCK pathway in chronic allograft dysfunction. Recent studies in animal models of 
allograft dysfunction strongly support this view. In a well established model of kidney 
transplantation Lewis rats acted as kidney graft recipients and Fisher rats as donors. 
Cyclosporine A was given for immunosuppression. One group of animals additionally 
received the specific ROCK-inhibitor Y-27632. Renal function deteriorated progressively in the 
group that received cyclosporine A alone and histology revealed the typical features of IF/TA. 
ROCK inhibition by Y-27632 significantly prevented the deterioration of kidney function, 
reduced proteinuria and preserved renal function. These effects were accompanied by down-
regulation of the expression of tubular MCP-1, RANTES, and phosphorylated NF-kB. The 
profibrotic TGF-ß1 and ┙-SMA, a marker of EMT, were downregulated by the treatment with 
Y-27632. These data indicated that the Rho/ROCK pathway is critically involved in renal 
interstitial inflammation and fibrosis, thus efficiently retarding the development of chronic 
allograft failure (Liu et al. 2009). The same group reported that atorvastatin, an inhibitor of the 
3-hydroxy-3-methylglutaryl-coenzyme A reductase, exerted protective effects in CAN (Zhang 
et al. 2007). Because 3-hydroxy-3-methylglutaryl-coenzyme A reductase interferes with 
isoprenylation and activation of Rho, these data support the view that inhibition of the 
Rho/ROCK pathway could be attractive in prevention of allograft nephropathy. Of note, these 
data confirmed what was seen earlier in a model of cardiac allograft vasculopathy in mice. 
Here, coronary remodeling in the allografts characterized by intimal thickening and 
perivascular fibrosis was dose-dependently suppressed by the ROCK-inhibitor fasudil. These 
data were strengthened as gene transfer of dominant-negative ROCK mimicked the effects of 
fasudil. Vascular inflammation and expression of profibrotic mediators were significantly 
reduced in this model (Hattori et al. 2004). Song et al. observed expression of RhoA and 
ROCK1 mRNA and protein in measangial and tubular cells in the Fisher-to-Lewis model of 
CAN. Interestingly, they found a negative correlation between RhoA/ROCK1 mRNA and the 
Banff score. MMF, a potent immunosuppressive drug used in solid organ transplantation 
attenuated CAN by downregulating the expression of RhoA/ROCK1 (Song et al. 2008). 
The data available suggest an important role of the Rho/ROCK pathway in chronic allograft 
dysfunction. Further studies also in humans are needed to support this view and possibly 
add a new therapeutic strategy to the nephrologist´s therapeutic options in preserving graft 
function. 
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2. Conclusion 
Recent experimental data provide promising data that kidney protection in diabetic 
nephropathy, urethral obstruction, hypertensive nephrosclerosis and chronic allograft 
nephropathy can be brought about by inhibition of the Rho/ROCK pathway. As reviewed 
above ROCK activity is involved in actin cytoskeletal organization, stress fiber formation, 
and cell contraction thereby controlling vascular smooth muscle contraction, endothelial 
barrier and leukocyte functions (e.g., cellular motility, migration, adhesion and 
transmigration). All of these aspects are important in the pathogenesis of the renal diseases 
discussed here. However, clinical trials are needed to develop future strategies and transfer 
new treatment options by ROCK-inhibition from bench to bedside. 
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